Signos, a purpose-driven metabolic health platform, has announced the launch of the Signos Glucose Monitoring System, the first FDA-cleared over-the-counter glucose monitoring system designed specifically for weight management. This milestone brings real-time, personalized health insights directly to individuals, empowering them to take control of their metabolic health without prescriptions or costly barriers.
The system integrates the Stelo by Dexcom glucose biosensor with Signos’ AI-powered platform, enabling users to see how food, activity, stress, sleep, and meal timing impact their glucose levels in real time. These insights translate into practical, personalized recommendations that help people manage weight, improve sleep, and reduce the risk of chronic diseases through understanding rather than restriction.
“Everyone deserves access to insights that help them live healthier, longer, more vibrant lives. Signos isn’t just about data; it’s about giving people ownership of their health journey,” said Sharam Fouladgar-Mercer, CEO and Founder of Signos. Actress and advisor Raven-Symoné also endorsed the platform, noting how it helps her stay mindful of her health and enjoy life with confidence.
With 73.6% of U.S. adults overweight or obese, 88% metabolically unhealthy, and global diabetes diagnoses projected to reach 1.3 billion by 2050, the launch of Signos offers a proactive, science-backed solution. Available now, it delivers real-time metabolic insights through a smartphone, giving millions a revolutionary way to monitor glucose and build healthier, lasting habits.